profit from every $100 of sales.
$0$100
OSR Holdings
$0.01+0.00% today
-53.2% in 1 year
1-year low $0.011-year high $0.03
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
OSR Holdings vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| OSR Holdings | No profit yet | ||
 Vertex Pharmaceuticals | 34.8× · Expensive | ||
 Regeneron Pharmaceuticals | 21.8× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.3× · Fair price |
AI analysis
An AI analyst reads OSR Holdings's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisNo annual statements on file yet.
Valuation
- –
- –
- 0.00
- 0.0×
- 5.0×
- –
- –
- -292.4%
- -870.7%
- 0.0%
Profitability
- 20.4%
- -631.0%
- -766.2%
- -366.8%
- -11.6%
- 30.6%
- -27.9%
- -13.0%
- -11.9%
- 7.9%
Growth
- –
- –
- −105.9%
- –
- −13.3%
Financial health
- -0.3×
- 0.06
- 2.6%
- -36.2×
- 0.16
- 0.15
- 0.02
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 25%of 952
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 13, 2026 | -0.09 | -0.29 | +69.0% |
| Mar 31, 2026 | -0.18 | -0.10 | −80.0% |
News
SBC Medical Group Holdings GAAP EPS of $0.15 beats by $0.03, revenue of $59M beats by $10.11MSeeking Alpha · Nov 13, 2026Conifer Holdings Q3 GAAP EPS of -$0.43Seeking Alpha · Nov 12, 2026Stock Market Today, Nov. 9: Grab Holdings Jumps on Record Adjusted EBITDA and Q3 Revenue BeatYahoo Finance · Nov 9, 2026DHT Holdings Q3 2026 Earnings PreviewSeeking Alpha · Nov 8, 2026Why ASML Holdings Fell in OctoberYahoo Finance · Nov 8, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/6Passes 0 of 6. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
47No pass
Benjamin Graham
59No pass
Philip Fisher
52No pass
Peter Lynch
–Not enough data
Joel Greenblatt
2No pass
Charlie Munger
50No pass
Terry Smith
41No pass
Questions about OSR Holdings
Is OSR Holdings a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 6 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the OSR Holdings AI analysis
What does OSR Holdings do?
OSR Holdings, Inc. operates as a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It is in Biotechnology.
Does OSR Holdings pay a dividend?
No. OSR Holdings does not pay a dividend at the moment.
How has OSR Holdings stock done over the past year?
Down 53.2% over the past twelve months, to $0.01. It traded between $0.01 and $0.03 and is 69.9% below its high.
Who are OSR Holdings's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with OSR Holdings's.
Prices: daily closes to Nov 6, 2026. Fundamentals: company reports via invest-like data.